GLUE Stock Overview
A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Monte Rosa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.93 |
| 52 Week High | US$12.40 |
| 52 Week Low | US$3.21 |
| Beta | 1.37 |
| 1 Month Change | -18.37% |
| 3 Month Change | 16.47% |
| 1 Year Change | 20.73% |
| 3 Year Change | -66.91% |
| 5 Year Change | n/a |
| Change since IPO | -67.28% |
Recent News & Updates
Monte Rosa Therapeutics: A First Assessment
Dec 04News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts
Nov 12
Recent updates
Monte Rosa Therapeutics: A First Assessment
Dec 04News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts
Nov 12Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
Oct 28We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Sep 23Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Mar 04We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Sep 24Shareholder Returns
| GLUE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | -3.6% | -2.4% |
| 1Y | 20.7% | -2.7% | 23.3% |
Return vs Industry: GLUE exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: GLUE underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| GLUE volatility | |
|---|---|
| GLUE Average Weekly Movement | 28.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLUE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GLUE's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 133 | Markus Warmuth | www.monterosatx.com |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers.
Monte Rosa Therapeutics, Inc. Fundamentals Summary
| GLUE fundamental statistics | |
|---|---|
| Market cap | US$425.75m |
| Earnings (TTM) | -US$119.39m |
| Revenue (TTM) | US$14.98m |
28.4x
P/S Ratio-3.6x
P/E RatioIs GLUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLUE income statement (TTM) | |
|---|---|
| Revenue | US$14.98m |
| Cost of Revenue | -US$1.80m |
| Gross Profit | US$16.78m |
| Other Expenses | US$136.17m |
| Earnings | -US$119.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.94 |
| Gross Margin | 112.03% |
| Net Profit Margin | -797.26% |
| Debt/Equity Ratio | 0% |
How did GLUE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Monte Rosa Therapeutics, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Richard J. Law | Credit Suisse |
| Michael Schmidt | Guggenheim Securities, LLC |